Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study
-
Published:2022-12-31
Issue:1
Volume:12
Page:
-
ISSN:2110-5820
-
Container-title:Annals of Intensive Care
-
language:en
-
Short-container-title:Ann. Intensive Care
Author:
Arrestier Romain, Bastard Paul, Belmondo Thibaut, Voiriot Guillaume, Urbina Tomas, Luyt Charles-Edouard, Gervais Adrian, Bizien Lucy, Segaux Lauriane, Ben Ahmed Mariem, Bellaïche Raphaël, Pham Taï, Ait-Hamou Zakaria, Roux Damien, Clere-Jehl Raphael, Azoulay Elie, Gaudry Stéphane, Mayaux Julien, Fage Nicolas, Ait-Oufella Hafid, Moncomble Elsa, Parfait Mélodie, Dorgham Karim, Gorochov Guy, Mekontso-Dessap Armand, Canoui-Poitrine Florence, Casanova Jean-Laurent, Hue Sophie, de Prost NicolasORCID
Abstract
Abstract
Background
Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or asymptomatic cases. Determining whether auto-Abs influence presentation and outcome of critically ill COVID-19 patients could lead to specific therapeutic interventions. Our objectives were to compare the severity at admission and the mortality of patients hospitalized for critical COVID-19 in ICU with versus without auto-Abs.
Results
We conducted a prospective multicentre cohort study including patients admitted in 11 intensive care units (ICUs) from Great Paris area hospitals with proven SARS-CoV-2 infection and acute respiratory failure. 925 critically ill COVID-19 patients were included. Auto-Abs neutralizing type I IFN-α2, β and/or ω were found in 96 patients (10.3%). Demographics and comorbidities did not differ between patients with versus without auto-Abs. At ICU admission, Auto-Abs positive patients required a higher FiO2 (100% (70–100) vs. 90% (60–100), p = 0.01), but were not different in other characteristics. Mortality at day 28 was not different between patients with and without auto-Abs (18.7 vs. 23.7%, p = 0.279). In multivariable analysis, 28-day mortality was associated with age (adjusted odds ratio (aOR) = 1.06 [1.04–1.08], p < 0.001), SOFA score (aOR = 1.18 [1.12–1.23], p < 0.001) and immunosuppression (aOR = 1.82 [1.1–3.0], p = 0.02), but not with the presence of auto-Abs (aOR = 0.69 [0.38–1.26], p = 0.23).
Conclusions
In ICU patients, auto-Abs against type I IFNs were found in at least 10% of patients with critical COVID-19 pneumonia. They were not associated with day 28 mortality.
Publisher
Springer Science and Business Media LLC
Subject
Critical Care and Intensive Care Medicine
Reference35 articles.
1. WHO Coronavirus (COVID-19) Dashboard [Internet]. https://covid19.who.int. Accessed 21 Feb 2022. 2. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. The Lancet [Internet]. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02796-3/fulltext. Accessed 20 Apr 2022. 3. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature Nature Publishing Group. 2020;584:430–6. 4. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. 5. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:4585.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|